CHF Treatment Landscape in 12 MM Discussed by Black Swan Analysis in Its New Report Published at MarketPublishers.com

18 Dec 2017 • by Natalie Aster

LONDON – Chronic heart failure (CHF) is a chronic progressive condition which affects the ability of heart to supply sufficient blood stream to the body. Aggravations of CHF are characterised by dyspnoea at rest or during physical activity and worsening volume retention, manifestative as congested lung and/or swollen legs and ankles. The disease is related to inflammatory, toxic and infective heart damage, structural, genetic and metabolic cardiac abnormalities, and also vascular risk factors, like smoking, couch-potato lifestyles, improper feeding and consumption of alcohol.

The major symptoms and co-morbidities for CHF encompass arterial hypertension, coronarism, auricular fibrillation, diabetes, syndrome X, obesity, renal dysfunction, COPD, pulmonary hypertension, sleep apnoea syndrome, and anaemia.

New research study “Epiomic Epidemiology Series: Chronic heart failure forecast in 12 major markets 2018–2028” drawn up by Black Swan Analysis provides an insightful, detailed analysis of the CHF market on a global level with a focus on 12 major markets.

It provides the present-day prevalence for the disease across 12 MM such as Canada, the USA, France, Germany, Spain, the UK, Italy, Russia, Japan, China, India and Brazil; with data bifurcated by gender and 5-year age cohort. The research offers an exhaustive assessment of the risk factors for CHF, diagnosis and prognosis of the condition, alongside distinctive variations based on geographical area and ethnicity. The report covers patient populations with the 2 types of CHF, and also quantifies several of the key symptoms and co-morbidities of CHF, presented together with the overall prevalence data. It includes an analysis and 10-year forecast of the sub-populations within the key disease by country.

Reasons to Buy:

  • Get trustworthy information on CHF patient numbers globally to target NPD, pricing strategies and launch plans.
  • Obtain details about the prevalence rates of the subdivided CHF types and high-potential patient segments.
  • Get deep insights into the clinical trials across various countries.
  • Understand how certain co-morbid conditions impact CHF prevalent population.
  • Discover what sub-populations within CHF require treatment.
  • Understand what the markets have the majority of CHF patients.

More new market research reports by our partner are available at its page.

CONTACTS

The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970
ps@marketpublishers.com
MarketPublishers.com